Merck & Co. is rounding out its March deal flurry with an antibody discovery pact that could be worth as much as $838 million ...

Merck & Co.’s experimental cholesterol pill slashed levels of the artery-clogging plaque far more than older tablets in the ...

March 31 (Reuters) - Biotech firm Infinimmune said on Tuesday it has entered into a deal with Merck, that could be worth up ...

March 30 () - Merck's oral drug reduced bad cholesterol by up to ‌64.6% in a late-stage trial, ‌the drugmaker said on Monday, ...

Merck and Terns Pharmaceuticals have agreed to a $6.7 billion all-cash buyout that delivers a prized leukemia asset to the ...

Merck & Co. agreed to buy Terns Pharmaceuticals Inc. for $6.7 billion, giving the multinational company access to a promising ...

Merck is eyeing a quick review for its lipid-lowering drug candidate enlicitide, which in December was awarded a Commissioner ...

March 25 (Reuters) - Merck said on Wednesday it would buy biotech Terns Pharma in a deal valued at up to $6.7 billion, as the ...

By Christy Santhosh March 30 (Reuters) - Drugmaker Merck said on Monday its oral drug met the main goal of meaningfully ...

Some investors and analysts believe the pharma’s $6.7 billion offer is justified given Terns’ recent stock run. Others are ...

Merck's $6.7 billion Terns acquisition bolsters its oncology pipeline while reinforcing its strong margins, steadily growing ...

In an R&D collaboration worth as much as $838 million, Merck will lean on Infinimmune to discover immune cell-directed ...